Emtora Biosciences

Emtora Biosciences is a San Antonio-based company specializing in the commercialization of eRapa, a targeted formulation of rapamycin. Their innovative approach aims to suppress the onset and recurrence of cancer, offering potential solutions for rare genetic diseases and various early-stage cancers or precancerous conditions.

With a focus on cancer prevention, Emtora Biosciences develops eRapa, a novel formulation of rapamycin that can extend life by delaying the onset of aging-related diseases and mitigating the effects of normal aging. Their leading indications include non-muscle invasive bladder cancer, low-grade prostate cancer, and Familial Adenomatous Polyposis (FAP), a rare genetic disease that leads to colon cancer, for which no current therapeutics exist.

Generated from the website